Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-88 + Docetaxel in Androgen-Independent Prostate Cancer
NCT00268593Phase 2Completed
- Sponsor
- Progen Pharmaceuticals
- Start
- Aug 2005
- Primary completion
- Feb 2008
- Modality
- Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of Muparfostat in prostate cancer (PCa), sponsored by Progen Pharmaceuticals. Started Aug 2005; status: completed.
02
Drugs
Muparfostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00268593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268593.